SLN News | Roxom Stocks

1 BTC

- USD

Loading market data...

Mkt Cap

$558.1M

Volume

1.07M

Next Earnings

November 5th

Chart Earnings News About Insider Filings

Silence Therapeutics (SLN) Upgraded to Buy: Here's WhySilence Therapeutics PLC (SLN) received an upgrade to Zacks Rank #2 (Buy) based on upward trends in earnings estimates. The company's consensus estimate has increased 5.7% over the past three months, positioning it in the top 20% of Zacks-covered stocks for estimate revisions. The upgrade reflects improving business fundamentals that could drive near-term stock price appreciation.Zacks Investment Research · Oct 13, 2026

Polycythemia Vera Market Set for Transformation: Key 9 Companies Expected to Enter by 2036 | DelveInsightThe polycythemia vera market is expected to expand significantly by 2036, growing at 8.9% CAGR from a 2025 valuation of approximately USD 2 billion. Nine major pharmaceutical companies are advancing next-generation therapies in various clinical development stages, with rusfertide from Protagonist Therapeutics and Takeda expected to be the first new entrant to market this year, potentially reshaping the treatment paradigm beyond current standard therapies like JAKAFI, BESREMi, and PEGASYS.GlobeNewswire Inc. · Apr 22, 2026

Australia Acute Respiratory Distress Syndrome Market Growth and Company Report 2025-2033 Featuring Silence Therapeutics, Gilead Sciences, Terumo, Getinge, Livanova, Medtronic, Fresenius, Nipro, PfizerThe Australia ARDS market is projected to grow from USD 24.82 million in 2024 to USD 44.79 million by 2033, driven by rising respiratory diseases, technological innovations, and post-COVID lung damage awareness.GlobeNewswire Inc. · Sep 4, 2025

BESREMi Achieves Strong Market Growth Amid Rising Demand for Polycythemia Vera TreatmentBESREMi, a FDA-approved treatment for polycythemia vera, is gaining market share due to its potential for better tolerability and lower risk of treatment-related malignancies compared to competitors like ruxolitinib and hydroxyurea.GlobeNewswire Inc. · Feb 20, 2025

RNA Based Therapeutic Market Size Expected to Reach USD 40.81 Bn by 2034The global RNA-based therapeutic market is expected to grow from $9.46 billion in 2025 to $40.81 billion by 2034, driven by the rising prevalence of genetic disorders and the demand for personalized medicine. North America and Asia Pacific are the key regional markets.GlobeNewswire Inc. · Feb 10, 2025

What 7 Analyst Ratings Have To Say About Silence TherapeuticsSilence Therapeutics (NASDAQ:SLN) underwent analysis by 7 analysts in the last quarter, revealing a spectrum of viewpoints from bullish to bearish. Summarizing their recent assessments, the table below illustrates the evolving sentiments in the past 30 days and compares them to the preceding months. Bullish Somewhat Bullish Indifferent Somewhat Bearish Bearish Total Ratings 5 2 0 0 0 Last 30D 1 0 0 0 0 1M Ago 0 1 0 0 0 2M Ago 0 0 0 0 0 3M Ago 4 1 0 0 0 In the assessment of 12-month price targets, analysts unveil insights for Silence Therapeutics, presenting an average target of $57.0, a high estimate of $75.00, and a low estimate of $42.00. Observing a 31.34% increase, the current average has risen from the previous average price target of $43.40. Understanding Analyst Ratings: A Comprehensive Breakdown In examining recent analyst actions, we gain insights into how financial experts perceive Silence Therapeutics. The following summary outlines key analysts, their recent evaluations, and adjustments to ratings and price targets. Analyst Analyst Firm Action Taken Rating Current Price Target Prior Price Target Keay Nakae Chardan Capital Maintains Buy $42.00 $42.00 Michael Ulz Morgan Stanley Maintains Overweight $45.00 $45.00 Patrick Trucchio HC Wainwright & Co. Maintains Buy $75.00 - Michael Ulz Morgan Stanley Raises Overweight $45.00 $29.00 Keay Nakae Chardan Capital Raises Buy $42.00 $26.00 Patrick Trucchio HC Wainwright & Co. Maintains Buy $75.00 $75.00 Patrick Trucchio HC Wainwright & Co. Maintains Buy $75.00 - Key Insights: Action Taken: Analysts frequently update their recommendations based on evolving market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Silence Therapeutics. This information ...Full story available on Benzinga.comBenzinga · May 17, 2024

Beyond The Numbers: 7 Analysts Discuss Silence Therapeutics Stock7 analysts have expressed a variety of opinions on Silence Therapeutics (NASDAQ:SLN) over the past quarter, offering a diverse set of opinions from bullish to bearish. The table below summarizes their recent ratings, showcasing the evolving sentiments within the past 30 days and comparing them to the preceding months. Bullish Somewhat Bullish Indifferent Somewhat Bearish Bearish Total Ratings 4 3 0 0 0 Last 30D 0 1 0 0 0 1M Ago 0 0 0 0 0 2M Ago 4 1 0 0 0 3M Ago 0 1 0 0 0 Analysts have set 12-month price targets for Silence Therapeutics, revealing an average target of $60.57, a high estimate of $75.00, and a low estimate of $42.00. This current average reflects an increase of 38.45% from the previous average price target of $43.75. Decoding Analyst Ratings: A Detailed Look The analysis of recent analyst actions sheds light on the perception of Silence Therapeutics by financial experts. The following summary presents key analysts, their recent evaluations, and adjustments to ratings and price targets. Analyst Analyst Firm Action Taken Rating Current Price Target Prior Price Target Michael Ulz Morgan Stanley Maintains Overweight $45.00 $45.00 Patrick Trucchio HC Wainwright & Co. Maintains Buy $75.00 - Michael Ulz Morgan Stanley Raises Overweight $45.00 $29.00 Keay Nakae Chardan Capital Raises Buy $42.00 $26.00 Patrick Trucchio HC Wainwright & Co. Maintains Buy $75.00 $75.00 Patrick Trucchio HC Wainwright & Co. Maintains Buy $75.00 - Kostas Biliouris BMO Capital Announces Outperform $67.00 - Key Insights: Action Taken: In response to dynamic market conditions and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their reaction to recent developments related to Silence Therapeutics. This insight gives a snapshot of ...Full story available on Benzinga.comBenzinga · Apr 22, 2024

Silence Therapeutics (SLN) Surges 5.7%: Is This an Indication of Further Gains?Silence Therapeutics (SLN) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions could translate into further price increase in the near term.Zacks Investment Research · Apr 12, 2024

These Analysts Boost Their Forecasts On Silence Therapeutics After Full Year 2023 ResultsSilence Therapeutics Plc (NASDAQ: SLN) reported a loss for 2023 on Wednesday. The company reported a loss per share of (38.9) pence for 2023, narrower than the (41.9) pence loss per share a year ago, according to data from Benzinga Pro. Collaboration revenues were £25.4 million versus £17.501 million a year ago. Net loss was £(43.3) million for 2023, compared to a net loss of £(40.5) million in 2022. “We ended ...Benzinga · Mar 14, 2024

What 4 Analyst Ratings Have To Say About Silence TherapeuticsProviding a diverse range of perspectives from bullish to bearish, 4 analysts have published ratings on Silence Therapeutics (NASDAQ:SLN) in the last three months. The table below provides a snapshot of their recent ratings, showcasing how sentiments have evolved over the past 30 days and comparing them to the preceding months. Bullish Somewhat Bullish Indifferent Somewhat Bearish Bearish Total Ratings 3 1 0 0 0 Last 30D 1 0 0 0 0 1M Ago 1 0 0 0 0 2M Ago 1 1 0 0 0 3M Ago 0 0 0 0 0 Providing deeper insights, analysts have established 12-month price targets, indicating an average target of $73.0, along with a high estimate of $75.00 and a low estimate of $67.00. Experiencing a 2.67% decline, the current average is now lower than the previous average price target of $75.00. Understanding Analyst Ratings: A Comprehensive Breakdown The standing of Silence Therapeutics among financial experts becomes clear with a thorough analysis of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets. Analyst Analyst Firm Action Taken Rating Current Price Target Prior Price Target Patrick Trucchio HC Wainwright & Co. Maintains Buy $75.00 $75.00 Patrick Trucchio HC Wainwright & Co. Maintains Buy $75.00 - Kostas Biliouris BMO Capital Announces Outperform $67.00 - Patrick Trucchio HC Wainwright & Co. Maintains Buy $75.00 - Key Insights: Action Taken: Analysts frequently update their recommendations based on evolving market conditions and company performance. Whether they 'Maintain', 'Raise' or ...Full story available on Benzinga.comBenzinga · Mar 13, 2024

SLNSilence Therapeutics Plc American Depository Share

SLN

Pay with—

Start Trading

Available Balance0.00

Your PositionYou don't own any SLN yet.

Related Tickers

Earnings

Mkt Cap

$539.5M

Volume

1.07M

Next Earnings

November 5th